https://healthsensemag.com/devices/cepheid-says-fda-cleared-xpert-hemorrhagic-fever-panelHealth Sense Magazineen2026-11-03Cepheid Says FDA Cleared Xpert Hemorrhagic Fever Panel for Four Viruses https://healthsensemag.com/explainers/cerus-red-cell-results-show-what-non-inferiorityHealth Sense Magazineen2026-11-03Cerus Red Cell Results Show What a Non-Inferiority Trial Does and Does Not Prove https://healthsensemag.com/treatments-trials/cerus-says-intercept-red-blood-cells-met-phaseHealth Sense Magazineen2026-11-03Cerus Says INTERCEPT Red Blood Cells Met Phase 3 RedeS Efficacy Goal https://healthsensemag.com/policy-regulation/fda-finalizes-cell-gene-therapy-potency-guidance-replacingHealth Sense Magazineen2026-11-03FDA Finalizes Cell and Gene Therapy Potency Guidance, Replacing 2011 Document https://healthsensemag.com/news/medtech-canada-seeks-zero-zero-tariffs-us-50Health Sense Magazineen2026-11-03Medtech Canada Seeks Zero-for-Zero Tariffs After US 50% Duties Reach Medical Technologies https://healthsensemag.com/business/rockwell-medical-agrees-buy-most-vantives-hemodialysis-businessHealth Sense Magazineen2026-11-03Rockwell Medical Agrees to Buy Most of Vantive's Hemodialysis Business for $125 Million https://healthsensemag.com/digital-health/samsung-starts-us-rollout-fda-cleared-sleep-apneaHealth Sense Magazineen2026-11-03Samsung Starts US Rollout of FDA-Cleared Sleep Apnea Feature on Galaxy Ring https://healthsensemag.com/digital-health/advamed-digital-health-board-approves-voluntary-data-accessHealth Sense Magazineen2026-11-02AdvaMed Digital Health Board Approves Voluntary Data Access Best Practices https://healthsensemag.com/business/dexcom-q3-revenue-rises-11-1-344-billionHealth Sense Magazineen2026-11-02Dexcom Q3 Revenue Rises 11% to $1.344 Billion; Company Raises 2026 Outlook https://healthsensemag.com/treatments-trials/fda-approves-sun-pharmas-ilumya-active-psoriatic-arthritisHealth Sense Magazineen2026-11-02FDA Approves Sun Pharma's Ilumya for Active Psoriatic Arthritis https://healthsensemag.com/policy-regulation/fda-lists-class-i-recall-werfens-hemosil-acustarHealth Sense Magazineen2026-11-02FDA Lists Class I Recall of Werfen's HemosIL AcuStar HIT Antibody Test